Kymera Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2019 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Kymera Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2019 to Q4 2023.
  • Kymera Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $162M, a 35.2% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $162M +$42.3M +35.2% Dec 31, 2023 10-K 2024-02-22
Q4 2022 $120M +$42.1M +54% Dec 31, 2022 10-K 2024-02-22
Q4 2021 $78M +$43.9M +129% Dec 31, 2021 10-K 2023-02-23
Q4 2020 $34.1M +$13.1M +62.7% Dec 31, 2020 10-K 2022-02-24
Q4 2019 $20.9M Dec 31, 2019 10-K 2021-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.